PSYCHODAL (Risperidone)
1. Disclaimer
This information is intended for educational and professional reference purposes only and does not replace the official prescribing information, patient leaflet, or individualized advice of a qualified physician or pharmacist. Risperidone is a prescription antipsychotic that can cause clinically important neurological, metabolic, cardiovascular, endocrine, and other adverse effects; treatment and dose selection should therefore be individualized and medically supervised.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
2. Summary
Psychodal contains risperidone, a second-generation (atypical) antipsychotic of the benzisoxazole class. Its principal pharmacological activity is related to antagonism of dopamine D2 and serotonin 5-HT2 receptors, with additional activity at α1-, α2-adrenergic and H1-histaminergic receptors. It is used principally in the treatment of schizophrenia and, depending on the applicable regulatory labeling, bipolar mania and certain behavioral symptoms in specific patient populations. ([DailyMed][1])
3. Brand Name
Psychodal®
The brand is marketed in Egypt by Delta Pharma. Current Egyptian market listings identify Psychodal as a risperidone-containing antipsychotic produced by Delta Pharma. ([Egypt Dwa][2])
4. Category
Therapeutic category: Antipsychotic
Pharmacological class: Second-generation (atypical) antipsychotic
ATC: N05AX08 – Risperidone. ([Electronic Medicines Compendium][3])
5. Active Ingredient
Risperidone
Risperidone is the active antipsychotic ingredient. Its principal active metabolite is 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity; the overall clinical effect reflects the combined active antipsychotic fraction. ([DailyMed][1])
6. Pharmaceutical Form & Strength
The Egyptian market presentations currently identified in publicly available Egyptian pharmacy/medicine listings are:
- Psychodal 1 mg, 10 orodispersible tablets
- Psychodal 1 mg, 30 film-coated tablets
- Psychodal 1 mg/mL oral solution, 30 mL
- Psychodal 2 mg, 10 orodispersible tablets
- Psychodal 2 mg, 30 film-coated tablets
- Psychodal 3 mg, 30 film-coated tablets
- Psychodal 4 mg, 30 film-coated tablets
These presentations are currently listed by Egyptian market sources, including listings updated in August 2026. Such commercial listings support current market availability but should not be treated as a substitute for a live Egyptian Drug Authority (EDA) regulatory record. ([Egypt Dwa][2])
The 1 mg/mL oral solution contains 1 mg risperidone per mL; the Delta Pharma insert identifies it specifically as an oral solution. ([Delta Pharma][4])
7. Manufacturer & Marketing Authorization Holder
Manufacturer: Delta Pharma S.A.E., Tenth of Ramadan City, Egypt. Delta Pharma confirms that it operates pharmaceutical manufacturing facilities in 10th of Ramadan City, and the Psychodal product documentation identifies Delta Pharma S.A.E. with the product. ([Delta Pharma][5])
Marketing Authorization Holder: No separate MAH from Delta Pharma was identified in the publicly accessible sources reviewed. For regulatory documentation, the exact current MAH should be confirmed against the applicable EDA authorization record.
8. Mechanism of Action
Risperidone is a monoaminergic antagonist with high affinity for serotonin 5-HT2 and dopamine D2 receptors. It also binds to α1- and α2-adrenergic and H1-histaminergic receptors. Its therapeutic effects in schizophrenia are believed to arise primarily from combined D2 and 5-HT2 receptor antagonism. Blockade of α1-adrenergic receptors contributes to the risk of orthostatic hypotension, while D2 antagonism contributes to extrapyramidal symptoms and prolactin elevation. ([DailyMed][1])
9. Spectrum of Activity
Psychodal is not an anti-infective drug and has no antibacterial, antiviral, or antifungal spectrum. Its therapeutic activity is within the central nervous system, particularly for psychotic and manic symptoms and, in appropriately selected patients and according to the applicable product labeling, certain severe behavioral disturbances. ([DailyMed][6])
10. Pharmacokinetics
Risperidone is well absorbed after oral administration. Peak plasma concentrations of risperidone occur at approximately 1 hour in current prescribing information, while the Delta Pharma insert reports approximately 1–2 hours. Food does not materially affect the rate or extent of absorption. Oral bioavailability is approximately 70%. ([DailyMed][1])
Risperidone is extensively metabolized, principally by CYP2D6, to 9-hydroxyrisperidone; a minor metabolic pathway involves N-dealkylation. The active moiety consists of risperidone plus 9-hydroxyrisperidone. Approximately 90% of risperidone and 77% of 9-hydroxyrisperidone are plasma-protein bound. ([DailyMed][1])
The apparent half-life of risperidone is approximately 3 hours in extensive metabolizers and about 20 hours in poor metabolizers; 9-hydroxyrisperidone has a half-life of approximately 21 hours in extensive metabolizers and 30 hours in poor metabolizers. The overall active moiety has an elimination half-life of approximately 20 hours. The statement that the active metabolite alone always has a 24-hour half-life is therefore an oversimplification. ([DailyMed][1])
Elimination occurs predominantly through the urine, with a smaller fecal contribution. Renal impairment substantially reduces clearance of the active fraction and requires dose reduction; hepatic impairment increases the free fraction of risperidone. ([DailyMed][1])
11. Indications
The principal established indication is schizophrenia. Current U.S. labeling also indicates risperidone for acute manic or mixed episodes associated with Bipolar I Disorder, alone or adjunctively with lithium or valproate, and for irritability associated with autistic disorder. ([DailyMed][6])
The publicly available Delta Pharma Psychodal insert additionally describes use for moderate-to-severe manic episodes associated with bipolar disorder, short-term treatment of persistent aggression in moderate-to-severe Alzheimer's dementia under defined conditions, and short-term symptomatic treatment of conduct disorder in children and adolescents aged 5–18 years. These are highly specific indications and should be interpreted according to the locally authorized product labeling; risperidone is not a general treatment for dementia-related psychosis because of the increased mortality risk in elderly patients with dementia. ([Delta Pharma][5])
The former statement that risperidone is routinely indicated simply to “alleviate affective symptoms associated with schizophrenia” is not sufficiently precise for an updated drug monograph and is therefore omitted as a standalone indication.
12. Administration
Risperidone is administered orally, once or twice daily depending on indication, regimen, formulation, and clinical response. Food does not materially affect absorption. ([DailyMed][1])
For schizophrenia, the Delta Pharma insert recommends an adult starting dose of 2 mg/day, increasing to 4 mg/day on the second day, followed by individualized adjustment; many patients benefit from 4–6 mg/day. Doses above 10 mg/day have not shown superior efficacy in the cited Psychodal insert and are associated with greater extrapyramidal toxicity. ([Delta Pharma][5])
For bipolar mania, the local insert describes an initial 2 mg once daily regimen with adjustments at intervals of at least 24 hours and a flexible range of 1–6 mg/day. Pediatric and special-population dosing differs substantially and must not be extrapolated from adult dosing. ([Delta Pharma][5])
Patients with renal or hepatic impairment generally require a lower starting dose and slower titration. Abrupt discontinuation should be avoided when possible; gradual withdrawal is recommended because abrupt cessation may cause withdrawal symptoms and recurrence of psychotic symptoms. ([Delta Pharma][5])
13. Method of Preparation
The listed Psychodal dosage forms are ready-to-use oral formulations and do not require reconstitution.
For the 1 mg/mL oral solution, the Delta Pharma documentation specifies oral administration and a graduated dosing device/dropper supplied with the bottle. ([Delta Pharma][4])
For an orodispersible tablet, remove the tablet carefully from the blister with dry hands and place it immediately on the tongue; it disintegrates within seconds and may be swallowed with or without water. The exact handling instructions supplied with the specific Psychodal pack should be followed. ([Electronic Medicines Compendium][7])
Film-coated tablets should be swallowed orally as directed and should not be altered unless the product's official instructions specifically permit division.
14. Contraindications
The principal contraindication is hypersensitivity to risperidone or any component of the specific formulation. Current risperidone labeling also identifies hypersensitivity to paliperidone as relevant because paliperidone is the active metabolite of risperidone. ([DailyMed][1])
Risperidone should not be used to treat dementia-related psychosis in elderly patients because antipsychotic treatment in this population is associated with increased mortality and cerebrovascular risk. ([DailyMed][6])
15. Warnings & Precautions
Important precautions include orthostatic hypotension, cardiovascular disease, QT prolongation risk, seizures, Parkinson's disease or Lewy body dementia, dysphagia/aspiration risk, falls, venous thromboembolism, leukopenia/neutropenia, and impaired cognition or motor performance. ([Delta Pharma][4])
Risperidone can cause extrapyramidal symptoms and tardive dyskinesia, and rare neuroleptic malignant syndrome, which requires urgent medical management. ([Delta Pharma][4])
Clinically important metabolic effects may include weight gain, hyperglycemia/diabetes, and lipid abnormalities; weight, glucose and other metabolic parameters should be monitored as clinically appropriate. ([DailyMed][1])
Risperidone commonly raises prolactin, potentially producing amenorrhea, galactorrhea, gynecomastia, sexual dysfunction, and reproductive effects. ([DailyMed][1])
The drug may also cause sedation or dizziness and can impair driving or machinery operation until the individual's response is known. ([Delta Pharma][4])
16. Drug Interactions
Clinically important interactions include:
- Strong CYP2D6 inhibitors, particularly fluoxetine and paroxetine, can increase risperidone exposure and may require reassessment of the dose.
- Strong CYP3A4/P-gp inducers, especially carbamazepine; rifampicin, phenytoin, and phenobarbital may reduce exposure to the active antipsychotic fraction and potentially reduce efficacy.
- Alcohol and other CNS depressants may increase sedation and impairment.
- Antihypertensive drugs may enhance hypotensive effects.
- Levodopa and dopamine agonists may have reduced efficacy because of dopamine receptor antagonism.
- Methylphenidate requires monitoring for extrapyramidal symptoms when doses of either drug are changed.
- Concomitant use with paliperidone is generally not recommended because paliperidone is risperidone's active metabolite and combined exposure may become additive. ([DailyMed][1])
Patients should provide their physician or pharmacist with a complete list of prescription medicines, non-prescription medicines, and supplements before treatment changes are made.
17. Side Effects
Common or frequently reported adverse effects include sedation/somnolence, parkinsonism or other extrapyramidal symptoms, akathisia, headache, dizziness, insomnia, anxiety/agitation, nausea, vomiting, constipation, dyspepsia, increased appetite, weight gain, fatigue, and blurred vision. ([DailyMed][1])
Clinically important but less common or rare reactions include tardive dyskinesia, seizures, significant hypotension, QT prolongation/arrhythmias, cerebrovascular events, neuroleptic malignant syndrome, severe metabolic disturbances, agranulocytosis, angioedema, venous thromboembolism, and priapism. ([DailyMed][1])
18. Use in Special Populations
Elderly: Start cautiously and titrate slowly. Elderly patients are more susceptible to adverse effects. Risperidone should not be used for dementia-related psychosis because of increased mortality and cerebrovascular risk. ([DailyMed][1])
Renal impairment: Reduced clearance of the active antipsychotic fraction necessitates lower doses and slower titration. ([DailyMed][1])
Hepatic impairment: Increased free risperidone concentrations may occur; lower starting doses and cautious titration are appropriate. ([Delta Pharma][5])
Pregnancy: Available human data have not established a clear increase in major birth defects, but antipsychotic exposure, particularly during the third trimester, may result in neonatal extrapyramidal and/or withdrawal symptoms. Treatment should therefore be based on an individualized benefit-risk assessment. ([DailyMed][1])
Breastfeeding: Risperidone and 9-hydroxyrisperidone can enter human milk. Reported infant effects include sedation, poor weight gain, jitteriness, and extrapyramidal symptoms; the mother's clinical need and the potential infant risk should be weighed carefully. ([DailyMed][1])
Children and adolescents: Pediatric indications and age limits are indication- and jurisdiction-specific. Current U.S. labeling supports use in selected adolescents for schizophrenia and bipolar mania and in children/adolescents for irritability associated with autistic disorder, whereas the publicly available Delta Pharma Psychodal insert has different local recommendations and specifically includes conduct disorder from age 5. Therefore, the locally authorized Psychodal leaflet must determine pediatric use in Egypt. ([DailyMed][1])
19. Storage Conditions
For the Psychodal oral solution, the Delta Pharma insert states store at room temperature. The exact storage temperature printed on the current commercial pack should be followed. ([Delta Pharma][4])
A historical Psychodal tablet reference states 15–30°C, in a dry place and protected from light; however, because this information could not be independently confirmed from a current official tablet leaflet, the more defensible wording is to follow the current package storage instructions rather than treating the historical 15–30°C statement as universally current. ([Drug Pamphlet][8])
Keep out of reach of children and do not use after the stated expiry date.
20. Additional Sections
Prescription status: Psychodal/risperidone is a prescription-only antipsychotic and should be used under medical supervision. ([Electronic Medicines Compendium][3])
Driving and machinery: Sedation, dizziness, visual effects, and cognitive/motor impairment may occur. Patients should avoid driving or operating machinery until their individual response is known. ([Delta Pharma][4])
Monitoring: Clinical monitoring should generally include response and extrapyramidal symptoms, weight, blood pressure when indicated, glucose/metabolic parameters, prolactin-related symptoms, and other investigations dictated by the patient's risk profile. ([DailyMed][1])
Overdose: Overdose may produce marked somnolence, extrapyramidal symptoms, hypotension, seizures, and cardiac rhythm abnormalities. Management is supportive; there is no specific antidote to risperidone. ([DailyMed][1])
Current Egyptian presentations: The publicly accessible Egyptian market sources reviewed currently list the seven Psychodal presentations described in Section 6. Availability can vary by pharmacy and supply status. ([Egypt Dwa][9])
21. Frequently Asked Questions (FAQ)
What is Psychodal?
Psychodal is a brand of risperidone, a second-generation antipsychotic used principally for schizophrenia and, according to applicable labeling, other psychiatric indications. ([DailyMed][1])
Is Psychodal the same as risperidone?
Yes. Psychodal contains risperidone as its active ingredient.
Can Psychodal be stopped suddenly?
Abrupt discontinuation is generally discouraged. Gradual withdrawal is recommended when clinically appropriate because withdrawal symptoms and recurrence of psychotic symptoms may occur. ([Electronic Medicines Compendium][10])
Does food affect Psychodal absorption?
No clinically important food effect on the absorption of oral risperidone has been demonstrated. ([DailyMed][1])
Can Psychodal cause weight gain or increased blood sugar?
Yes. Weight gain, hyperglycemia and other metabolic changes are recognized adverse effects, so appropriate monitoring is important. ([DailyMed][1])
Can Psychodal increase prolactin?
Yes. Risperidone is relatively prominent among antipsychotics in its tendency to increase prolactin, which may lead to menstrual, breast, sexual, and fertility-related effects. ([DailyMed][1])
Can Psychodal be used during pregnancy or breastfeeding?
It may sometimes be clinically necessary, but use requires an individualized benefit-risk assessment. Exposure during late pregnancy can cause neonatal extrapyramidal or withdrawal symptoms, and risperidone is present in breast milk. ([DailyMed][1])
22. References
- Delta Pharma – Psychodal (Risperidone) 1 mg/mL Oral Solution, official product insert. Includes composition, indications, administration, precautions, interactions, pharmacokinetics, adverse effects and storage information. ([Delta Pharma][5])
- DailyMed – Risperidone Tablets, current U.S. prescribing information, revised February 2026. Provides current indications, dosing, contraindications, warnings, interactions, pregnancy/lactation information and pharmacokinetics. ([DailyMed][6])
- electronic Medicines Compendium (emc) – Risperidone 1 mg orodispersible tablets, revised March 2025. Provides current orodispersible-tablet administration instructions, adverse effects, precautions and interactions. ([Electronic Medicines Compendium][11])
- WHO ATC/DDD materials – Risperidone, ATC N05AX08. ([World Health Organization][12])
- Delta Pharma – Who We Are. Current company information confirming pharmaceutical manufacturing operations in 10th of Ramadan City, Egypt. ([Delta Pharma][13])
- Current Egyptian market listings for Psychodal 1 mg, 1 mg/mL, 2 mg, 3 mg and 4 mg presentations, accessed in August 2026, used only to corroborate current market-listed presentations and not as a substitute for official regulatory authorization data. ([Egypt Dwa][2])